307 related articles for article (PubMed ID: 25239681)
1. Assessing the impact of CMF-like/Anthracycline-based/Anthracycline-Taxane-based/dose-dense chemotherapy in dependency of positive axillary lymph nodes/hormone receptor-status/grading/T-stage on survival - A retrospective multi-centre cohort study of 3677 patients receiving adjuvant chemotherapy.
Schwentner L; Wöckel A; König J; Janni W; Blettner M; Kreienberg R; Van Ewijk R;
Eur J Cancer; 2014 Nov; 50(17):2905-15. PubMed ID: 25239681
[TBL] [Abstract][Full Text] [Related]
2. Sequential adjuvant docetaxel and anthracycline chemotherapy for node positive breast cancers: a retrospective study.
Bulent Akinci M; Algin E; Inal A; Odabas H; Berk V; Coskun U; Uyeturk U; Isikdogan A; Aksoy S; Civelek B; Sevinc A; Buyukberber S
J BUON; 2013; 18(2):314-20. PubMed ID: 23818340
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of the factors affecting pathologic complete response to neoadjuvant chemotherapy in breast cancer patients].
Sun B; Song ST; Jiang ZF; Wang T; Zhang SH; Meng XY; Li XB; Yu CZ; Wu SK
Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):38-42. PubMed ID: 23648298
[TBL] [Abstract][Full Text] [Related]
4. Taxane-based combinations as adjuvant chemotherapy for node-positive ER-positive breast cancer based on 2004-2009 data from the Breast Cancer Registry of the Japanese Breast Cancer Society.
Hojo T; Masuda N; Iwamoto T; Niikura N; Anan K; Aogi K; Ohnishi T; Yamauchi C; Yoshida M; Kinoshita T; Masuoka H; Sagara Y; Sakatani T; Kojima Y; Tsuda H; Kumamaru H; Miyata H; Nakamura S
Breast Cancer; 2020 Jan; 27(1):85-91. PubMed ID: 31327134
[TBL] [Abstract][Full Text] [Related]
5. Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients.
Watanuki R; Hayashida T; Kawai Y; Kikuchi M; Nakashoji A; Yokoe T; Toyota T; Seki T; Takahashi M; Kitagawa Y
Int J Clin Oncol; 2019 Jul; 24(7):807-814. PubMed ID: 30810890
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer.
Shimizu C; Masuda N; Yoshimura K; Tsuda H; Mano M; Ando M; Tamura K; Fujiwara Y
Jpn J Clin Oncol; 2009 Aug; 39(8):484-90. PubMed ID: 19477897
[TBL] [Abstract][Full Text] [Related]
7. pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials.
Reinisch M; Huober J; von Minckwitz G; Blohmer JU; Denkert C; Hanusch C; Jackisch C; Kümmel S; Schneeweiss A; Rhiem K; Lederer B; Untch M; Nekljudova V V; Loibl S
Breast; 2017 Apr; 32():73-78. PubMed ID: 28063331
[TBL] [Abstract][Full Text] [Related]
8. Taxane-based regimens as adjuvant treatment for breast cancer: a retrospective study in egyptian cancer patients.
Azim HA; Abdal-Kader YS; Mousa MM; Malek RA; Abdalmassih MK; Ibrahim NY
Asian Pac J Cancer Prev; 2015; 16(1):65-9. PubMed ID: 25640392
[TBL] [Abstract][Full Text] [Related]
9. Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy.
Bozovic-Spasojevic I; Ameye L; Paesmans M; Larsimont D; Di Leo A; Dolci S; Piccart M; de Azambuja E; Loi S
Breast; 2014 Aug; 23(4):473-81. PubMed ID: 24768477
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.
Fujii T; Le Du F; Xiao L; Kogawa T; Barcenas CH; Alvarez RH; Valero V; Shen Y; Ueno NT
JAMA Oncol; 2015 Dec; 1(9):1311-8. PubMed ID: 26402167
[TBL] [Abstract][Full Text] [Related]
11. Comparison of three adjuvant chemotherapy regimes using an extended log-logistic model in women with operable breast cancer.
Faradmal J; Kazemnejad A; Khodabakhshi R; Gohari MR; Hajizadeh E
Asian Pac J Cancer Prev; 2010; 11(2):353-8. PubMed ID: 20843115
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.
Mackey JR; Martin M; Pienkowski T; Rolski J; Guastalla JP; Sami A; Glaspy J; Juhos E; Wardley A; Fornander T; Hainsworth J; Coleman R; Modiano MR; Vinholes J; Pinter T; Rodríguez-Lescure A; Colwell B; Whitlock P; Provencher L; Laing K; Walde D; Price C; Hugh JC; Childs BH; Bassi K; Lindsay MA; Wilson V; Rupin M; Houé V; Vogel C;
Lancet Oncol; 2013 Jan; 14(1):72-80. PubMed ID: 23246022
[TBL] [Abstract][Full Text] [Related]
13. [Adjuvant chemotherapy based on evidence-based medicine for breast cancer patients].
Tokudome N; Ito Y
Gan To Kagaku Ryoho; 2006 Mar; 33(3):318-23. PubMed ID: 16531711
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase II alpha and microtubule-associated protein-tau as a predictive marker in axillary lymph node positive breast cancer.
Won HS; Lee KE; Sung SH; Choi MY; Jo JY; Nam EM; Mun YC; Seong CM; Lee SN
Tumori; 2014; 100(1):80-6. PubMed ID: 24675496
[TBL] [Abstract][Full Text] [Related]
15. Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG).
Saloustros E; Malamos N; Boukovinas I; Kakolyris S; Kouroussis C; Athanasiadis A; Ziras N; Kentepozidis N; Makrantonakis P; Polyzos A; Christophyllakis C; Georgoulias V; Mavroudis D
Breast Cancer Res Treat; 2014 Dec; 148(3):591-7. PubMed ID: 25399229
[TBL] [Abstract][Full Text] [Related]
16. 3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study.
Ferreira Filho AF; Crown J; Cardoso F; Nogaret JM; Duffy K; Dolci S; Rowan S; O'Higgins N; Batter V; Paesmans M; Piccart MJ; Di Leo A
Anticancer Res; 2002; 22(4):2471-6. PubMed ID: 12174946
[TBL] [Abstract][Full Text] [Related]
17. [Recent perspectives second-line chemotherapy for breast cancer].
Fujiuchi N; Ohokubo K; Saeki T; Sasaki Y
Gan To Kagaku Ryoho; 2005 Jan; 32(1):11-4. PubMed ID: 15675574
[TBL] [Abstract][Full Text] [Related]
18. [Retrospective analysis of trastuzumab treatment in 141 patients with Her-2 positive breast cancer].
Wang Y; Li JJ; DI GH; Lu JS; Wu J; Liu GY; Hu XC; Wang ZH; Yang WT; Shao ZM
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):864-7. PubMed ID: 21223695
[TBL] [Abstract][Full Text] [Related]
19. The effect of obesity on pathological complete response and survival in breast cancer patients receiving uncapped doses of neoadjuvant anthracycline-taxane-based chemotherapy.
Farr A; Stolz M; Baumann L; Bago-Horvath Z; Oppolzer E; Pfeiler G; Seifert M; Singer CF
Breast; 2017 Jun; 33():153-158. PubMed ID: 28395233
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers.
Lee HJ; Park IA; Song IH; Kim SB; Jung KH; Ahn JH; Ahn SH; Kim HH; Gong G
PLoS One; 2015; 10(9):e0137885. PubMed ID: 26394326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
